average weight loss on retatrutide produces up to 30.3% in Phase 3 trial retatrutide clinical trial updates Retatrutide,

The difference is not simply luck or medication response

Detailed week-by-week protocol This expanded chart includes practical guidance for each phase: Phase 1: Initiation (Weeks 1-4) Dose: 2 mg once weekly What to expect: Reduced appetite (often noticed within days) Possible mild nausea (usually transient) Some reduction in food cravings Minimal weight loss during this phase Tips: Establish your injection routine Track symptoms in a journal Note your baseline weight and measurements Don't expect dramatic results yet Side effects at this phase: Usually mild if present Most common: slight nausea, mild fullness If severe: contact your provider before escalating Phase 2: First escalation (Weeks 5-8) Dose: 4 mg once weekly What to expect: More noticeable appetite suppression Possible increase in nausea (typically resolves in 1-2 weeks) Beginning of measurable weight loss Some may notice improved energy Tips: Eat smaller, more frequent meals Avoid high-fat and fried foods Stay well-hydrated (minimum 64 oz water daily) If nausea is severe, hold at 2 mg for 2 more weeks Side effects at this phase: GI symptoms often peak here Nausea, occasional vomiting, bloating possible Most symptoms improve by week 7-8 Phase 3: Building dose (Weeks 9-12) Dose: 6 mg once weekly What to expect: Significant appetite reduction Noticeable weight loss (often 5-10% by week 12) Body adapting to medication Side effects often improving from week 5-8 Tips: Continue hydration focus Prioritize protein intake to preserve muscle Consider light exercise if energy permits Monitor for any new symptoms Note: Some protocols skip 6 mg and go directly from 4 mg to 8 mg

Studies also show it upregulates genes linked to healing and downregulates those associated with damaging inflammation [2]

The muscles are sutured back together along the midline, narrowing the torso and restoring the abdominal wall

Reduced HRV during the early treatment phase is expected and typically normalizes during the adaptation phase

What we care about clinically falls, disability, frailty progression, all-cause mortality depends more on function than on mass per se